Brian Williamson

Mar 11, 2024 | nature.com | Craig A Magaret |Allan C. deCamp |Morgane Rolland |Michal Juraska |Brian Williamson |James Ludwig | +23 more

AbstractIn the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs.